Paediatric microbial keratitis prognosis more effective with intensive drug therapy

Article

Early diagnosis, intensive drug therapy, and timely surgical intervention are all associated with the improved prognosis of paediatric microbial keratitis.

Early diagnosis, intensive drug therapy, and timely surgical intervention are all associated with the improved prognosis of paediatric microbial keratitis, states an investigation in the European Journal of Ophthalmology.

Dr Xiusheng Song et al., Department of Ophthalmology, Renmin Hospital of Wuhan University, China, studied the medical records of 80 eyes of 76 children with non-viral microbial keratitis. The outcome measures included demographic features, predisposing factors, clinical features, etiologic microorganisms, and treatment outcomes.

Of the patients studied, 76 met the inclusion criteria. It was found that the most common predisposing factor of microbial keratitis was trauma, with 39 of 80 patients presenting as culture positive. In 21 cases bacterial isolates were found and fungi was found in 19 cases.

Out of the 58 examined eyes, 50 presented with a best-corrected visual acuity of 20/200 or better at the last follow-up. The most frequent bacteria that were isolated were coagulase-negative Staphylococcus.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.